International Stem Cell (OTCMKTS: ISCO) is one of 536 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare International Stem Cell to related companies based on the strength of its risk, institutional ownership, dividends, valuation, profitability, analyst recommendations and earnings.
This is a summary of recent ratings for International Stem Cell and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|International Stem Cell||0||0||0||0||N/A|
|International Stem Cell Competitors||4081||11816||26116||885||2.55|
As a group, “Pharmaceutical preparations” companies have a potential upside of 64.80%. Given International Stem Cell’s competitors higher probable upside, analysts plainly believe International Stem Cell has less favorable growth aspects than its competitors.
Valuation and Earnings
This table compares International Stem Cell and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|International Stem Cell||$7.46 million||-$6.06 million||-1.03|
|International Stem Cell Competitors||$2.19 billion||$165.99 million||-1.47|
International Stem Cell’s competitors have higher revenue and earnings than International Stem Cell. International Stem Cell is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares International Stem Cell and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|International Stem Cell||-23.26%||-123.16%||-31.68%|
|International Stem Cell Competitors||-1,977.77%||-91.10%||-27.39%|
Volatility & Risk
International Stem Cell has a beta of -0.22, indicating that its share price is 122% less volatile than the S&P 500. Comparatively, International Stem Cell’s competitors have a beta of 0.99, indicating that their average share price is 1% less volatile than the S&P 500.
Institutional & Insider Ownership
46.2% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 83.2% of International Stem Cell shares are owned by company insiders. Comparatively, 15.1% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
International Stem Cell competitors beat International Stem Cell on 7 of the 10 factors compared.
International Stem Cell Company Profile
International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company's human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a Website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. The company was founded in 2001 and is headquartered in Carlsbad, California.
Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.